Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Nepstar Downsizes, Cuts Store Personnel by 11.7%, To Weather Global Crisis and China’s Economic Slowdown

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China Nepstar, one of China's leading drugstore chain operators, is downsizing in order to weather the global financial crisis and the country's own economic slowdown, according to the company's chairman

You may also be interested in...



Deals Of The Week: GlaxoSmithKline/Chroma, Biovail/Cambridge ...

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.

China Drugstore Chain Nepstar Sees Acquisition Opportunities Emerging From Economic Crisis

BEIJING - As a financial maelstrom churns across the West and threatens China's economic growth rates, China Nepstar Chain Drugstore sees a rainbow of opportunity; small private pharmacies tossed about in the current storm could become takeover targets, according to Nepstar officials

China Drugstore Chain Nepstar Sees Acquisition Opportunities Emerging From Economic Crisis

BEIJING - As a financial maelstrom churns across the West and threatens China's economic growth rates, China Nepstar Chain Drugstore sees a rainbow of opportunity; small private pharmacies tossed about in the current storm could become takeover targets, according to Nepstar officials

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067342

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel